Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial

COVID-19

COVID-19 is an infectious disease caused by the novel coronavirus SARS-CoV-2, first detected in Wuhan, China, in December 2019. The outbreak rapidly escalated into a global pandemic, prompting widespread public health measures, travel restrictions, and economic disruptions. COVID-19 has had profound effects on global markets, supply chains, and healthcare systems, influencing policy decisions and investor sentiment worldwide.

If You Invested $1,000 In Moderna Stock at IPO, Here's How Much You'd Have Now
If You Invested $1,000 In Moderna Stock at IPO, Here's How Much You'd Have Now
COVID-19 Made Moderna Famous: Cancer Could Define Its Future
COVID-19 Made Moderna Famous: Cancer Could Define Its Future
Rand Paul Escalates Long-Running COVID Origins Fight, Subpoenas Anthony Fauci: 'If You Lie To Congress…You Will Answer For It'
Rand Paul Escalates Long-Running COVID Origins Fight, Subpoenas Anthony Fauci: 'If You Lie To Congress…You Will Answer For It'
COVID-19 Made Moderna Famous: Cancer Could Define Its Future
COVID-19 Made Moderna Famous: Cancer Could Define Its Future
Rand Paul Escalates Long-Running COVID Origins Fight, Subpoenas Anthony Fauci: 'If You Lie To Congress…You Will Answer For It'
Rand Paul Escalates Long-Running COVID Origins Fight, Subpoenas Anthony Fauci: 'If You Lie To Congress…You Will Answer For It'
Ron DeSantis Says 'I Was Ready To Sign' Ivermectin Bill—His Own Party Killed It
Ron DeSantis Says 'I Was Ready To Sign' Ivermectin Bill—His Own Party Killed It
BioNTech Slides As Vaccine Sales Drop, Restructuring Plan Takes Shape
BioNTech Slides As Vaccine Sales Drop, Restructuring Plan Takes Shape

COVID-19 Recent News

Moderna's COVID-19 Vaccine Update Boosts Antibodies 16-Fold, Data Shows
Moderna's COVID-19 Vaccine Update Boosts Antibodies 16-Fold, Data Shows
Moderna's 2025-2026 mNEXSPIKE showed strong immune response and safety in Phase 4 trials, reinforcing FDA approval for the LP.8.1-targeting formula.
Pfizer, BioNTech Roll Out COVID-19 Update That Boosts Antibodies 4-Fold In High-Risk Adults
Pfizer, BioNTech Roll Out COVID-19 Update That Boosts Antibodies 4-Fold In High-Risk Adults
Pfizer and BioNTech's LP.8.1 COVID-19 vaccine boosts antibodies 4-fold in high-risk adults, with no new safety concerns reported.
Moderna Expands Cost-Cutting Program By Up To $1.7 Billion, FDA Approval For Flu/COVID-19 Combo Shot Delayed Into 2026
Moderna Expands Cost-Cutting Program By Up To $1.7 Billion, FDA Approval For Flu/COVID-19 Combo Shot Delayed Into 2026
Moderna reaffirms 2025 revenue guidance of $1.5 billion–$2.5 billion, cuts 2027 cost forecast by up to $1.7 billion, and targets 2026 approval for its flu/COVID combo shot.
Novavax Covid Vaccine Shows Milder Side Effects Than Pfizer-BioNTech's Shot: Study
Novavax Covid Vaccine Shows Milder Side Effects Than Pfizer-BioNTech's Shot: Study
Novavax updated Covid vaccine showed fewer and milder side effects than Pfizer-BioNTech's in a Utah study.
Pfizer Shares Are Down Today: What's Going On?
Pfizer Shares Are Down Today: What's Going On?
Pfizer shares are trading lower Wednesday after a Wall Street Journal report revealed that U.S. prosecutors are investigating a claim about the timing of Pfizer's COVID-19 vaccine announcement.
'Black Swan' Hedge Fund Posts 4,000% Profits During COVID-19 Market Crash: Here's How
'Black Swan' Hedge Fund Posts 4,000% Profits During COVID-19 Market Crash: Here's How
Universa Investments hedge fund, led by billionaire investor Mark Spitznagel, posted a 4,144% return in a single quarter during the COVID-19 market crash in early 2020. Here's a look at how he did it.
Invivyd Touts Encouraging Data From COVID-19 Antibody Trial, Stock Jumps
Invivyd Touts Encouraging Data From COVID-19 Antibody Trial, Stock Jumps
Invivyd data shows strong potency and prolonged antibody levels in trials. Q4 Pemgarda revenue rose 48% to $13.8 million.
Robert Kennedy Jr. Faces Senate Confirmation Hearings As Bird Flu Concerns Grow: Caroline Kennedy Says Cousin 'Predator' Unfit For Office
Robert Kennedy Jr. Faces Senate Confirmation Hearings As Bird Flu Concerns Grow: Caroline Kennedy Says Cousin 'Predator' Unfit For Office
Robert F. Kennedy, Jr. will begin Senate confirmation hearings on Wednesday as President Donald Trump's pick to lead the Department of Health and Human Services. 
US Records First Human Bird Flu Death, High Levels Of Respiratory Illnesses: Vaccine Stocks Rally
US Records First Human Bird Flu Death, High Levels Of Respiratory Illnesses: Vaccine Stocks Rally
The Louisiana Department of Health on Monday reported the first human death in the U.S. related to the H5N1 bird flu virus. The CDC is also reporting high levels of acute respiratory illnesses nationwide. 
Cathie Wood's Wednesday Exodus: Moderna And Jack Dorsey's Block Stocks Get Dumped
Cathie Wood's Wednesday Exodus: Moderna And Jack Dorsey's Block Stocks Get Dumped
On Wednesday, Ark Invest, led by Cathie Wood, made significant trades in Moderna Inc. (NASDAQ:MRNA) and Square Inc. (NYSE:SQ). The Moderna Trade
Moderna Hit With Another Lawsuit Related To Key COVID-19 Vaccine Technology
Moderna Hit With Another Lawsuit Related To Key COVID-19 Vaccine Technology
Northwestern University has filed a lawsuit against Moderna, alleging the company used its patented lipid nanoparticle technology without permission in the development of its COVID-19 vaccines.
Cathie Wood Continues To Sell Shares Of Jack Dorsey's Bitcoin-Focused Company Block — Ark Also Dumps Moderna, Robinhood Stock
Cathie Wood Continues To Sell Shares Of Jack Dorsey's Bitcoin-Focused Company Block — Ark Also Dumps Moderna, Robinhood Stock
On Wednesday, Cathie Wood’s Ark Invest made significant trades involving Block Inc (NYSE:SQ) and Moderna Inc (NASDAQ:MRNA). The SQ Trade
Cathie Wood's Ark Invest Dumps Over $9M In Moderna Stock — Even With Post-COVID Plans On The Table
Cathie Wood's Ark Invest Dumps Over $9M In Moderna Stock — Even With Post-COVID Plans On The Table
On Thursday Oct 10, 2024 Cathie Wood-Led Ark Invest sold over $9 million worth of Moderna stock.
Alnylam's Concedes Its Patent Infringement Case Against Moderna's COVID-19 Vaccine
Alnylam's Concedes Its Patent Infringement Case Against Moderna's COVID-19 Vaccine
Alnylam Pharmaceuticals has conceded that Moderna's products do not infringe on its patents, as a court ruling determined. Both companies have agreed to dismiss the case without prejudice for possible future actions.
Gilead Sciences Recalls One Lot Of Its COVID-19 Treatment Due To Presence Of Glass Particles
Gilead Sciences Recalls One Lot Of Its COVID-19 Treatment Due To Presence Of Glass Particles
Gilead Sciences has recalled one lot of its COVID-19 treatment, Veklury (remdesivir), due to glass particles found in vials. Gilead is notifying distributors to cease use and return the remaining vials.
Cannabis Use Linked To Improved COVID-19 Outcomes, New Study Suggests
Cannabis Use Linked To Improved COVID-19 Outcomes, New Study Suggests
Explore how the latest study suggests cannabis use linked to improved COVID-19 outcomes, highlighting potential health benefits.
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Here's a look at five stocks that saw increased attention from Benzinga readers during the week and the reasons why.
Mark Zuckerberg's Admission Of Censorship A 'Beautiful Thing,' Says Vivek Ramaswamy: 'I Respect Him' For Admitting His Mistake
Mark Zuckerberg's Admission Of Censorship A 'Beautiful Thing,' Says Vivek Ramaswamy: 'I Respect Him' For Admitting His Mistake
Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved